Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.73 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.73 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 4/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11459045 | 0.91 | PTGS1 (0.65) | PTGS1AKR1C3AKR1C2GAATSHR | |
| SCHEMBL11469671 | 0.89 | PTGS1 (0.63) | PTGS1AKR1C3AKR1C2GAATSHR | |
| SCHEMBL11460823 | 0.89 | PTGS1 (0.63) | PTGS1AKR1C3AKR1C2GAATSHR | |
| SCHEMBL11281357 | 0.85 | PTGS1 (0.53) | PTGS1AKR1C3AKR1C2GAATSHR | |
| SCHEMBL31074330 | 0.85 | PTGS1 (0.93) | PTGS1AKR1C3AKR1C2GAATSHR | |
| 6-Methoxy-2-Naphthylacetic Acid SCHEMBL253759 | 0.84 | AKR1C3 (1.00) | PTGS1AKR1C3AKR1C2GAATSHR | |
| SCHEMBL153055 | 0.84 | GAA (0.74) | PTGS1AKR1C3AKR1C2GAATSHR | |
| SCHEMBL30049382 | 0.84 | GAA (0.74) | PTGS1AKR1C3AKR1C2GAATSHR | |
| SCHEMBL11286529 | 0.83 | PTGS1 (0.59) | PTGS1AKR1C3AKR1C2GAATSHR | |
| Methane SCHEMBL11413480 | 0.83 | PTGS1 (0.90) | PTGS1AKR1C3AKR1C2GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105111054-A | Curcumin analogue with enlarged conjugated system and preparation method and application thereof | UNIV LIAOCHENG | 2015-12-02 | — | — | CN | claimed |
| CN-105111054-A | Curcumin analogue with enlarged conjugated system and preparation method and application thereof | UNIV LIAOCHENG | 2015-12-02 | — | — | CN | disclosed |
| US-7320982-B2 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-β 1 | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | disclosed |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | SANOFI-AVENTIS (FR) | 2004-08-12 | — | — | US | disclosed |
| US-6693118-B2 | E.G., 1-(2-(6,7-METHYLENEDIOXYNAPHTH-2-YL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE AND 1-2-(4-CYCLOHEXENYLPHENYL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6 -TETRAHYDROPYRIDINE; apoptosis inhibition; treatment of graft rejection or of acute or chronic rheumatoid arthritis | SANOFI-SYNTHELABO (FR) | 2004-02-17 | — | — | US | disclosed |
| US-20020091143-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 | SANOFI-AVENTIS (FR) | 2002-07-11 | — | — | US | disclosed |
| US-6342505-B1 | inhibiting apoptosis using xaliproden hydrochloride, or other tetrahydropyridine derivatives | SANOFI-SYNTHELABO (FR) | 2002-01-29 | — | — | US | disclosed |
| US-5618822-A | N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them | SANOFI (FR) | 1997-04-08 | — | — | US | disclosed |
| US-5599941-A | N-substituted trifluoromethylphenyltetrahydropyridines process for the preparation thereof intermediates in said process and pharmaceutical compositions containing them | SANOFI (FR) | 1997-02-04 | — | — | US | disclosed |
| US-5596101-A | N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them | SANOFI (FR) | 1997-01-21 | — | — | US | disclosed |
| US-5559238-A | N-substituted trifluoromethylphenyltetrahydropyridenes process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them | SANOFI (FR) | 1996-09-24 | — | — | US | disclosed |
| US-5462945-A | N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them | SANOFI (FR) | 1995-10-31 | — | — | US | disclosed |
| US-5281606-A | N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them | SANOFI (FR) | 1994-01-25 | — | — | US | disclosed |
| US-4327022-A | Heterocyclic alkyl naphthols | STERLING DRUG INC. (US) | 1982-04-27 | — | — | US | disclosed |
| US-4169108-A | 5(OR 6)-[(Substituted-amino)alkyl]-2,3-naphthalenediols | STERLING DRUG INC. (US) | 1979-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091143-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 | TGFB1, TGFBR1, TGFB2 | PTGS1 25/4885AKR1C3 2797/4885AKR1C2 3110/4885 |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | TGFB1, TGFBR1, TGFB2 | PTGS1 26/4885AKR1C3 2995/4885AKR1C2 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.